Nefrocitran (Potassium Citrate)

Potassium citrate, the active ingredient in Nefrocitran, is an alkalinizing agent presented as an oral formulation for oral use. It is employed to raise urinary pH, helping prevent calcium kidney stones and to correct metabolic acidosis in patients requiring potassium supplementation. It is also indicated for patients with low urinary citrate levels.

GNH USA supplies Nefrocitran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable logistics for global distribution.

Nefrocitran, a urinary alkalinizer, is used in conditions where raising urinary pH or correcting systemic acidosis is beneficial. - Calcium kidney stones: helps prevent stone formation by increasing urinary citrate and pH. - Metabolic acidosis: assists in correcting systemic acid‑base imbalance by providing bicarbonate precursors. - Low urinary citrate: raises citrate concentration to inhibit calcium crystallization. - Renal tubular acidosis: alkalinizes urine and supports acid excretion in distal or proximal RTA. - Potassium supplementation: provides potassium ions for patients needing supplemental potassium while alkalinizing urine.

Potassium citrate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal cramping or flatulence. - Taste alteration: a mild metallic or salty taste in the mouth. - Increased urinary frequency: due to higher fluid intake or diuresis.

Serious or Rare Side Effects: - Hyperkalemia: elevated blood potassium levels, potentially causing cardiac arrhythmias. - Metabolic alkalosis: excessive rise in systemic pH leading to confusion or muscle twitching. - Allergic reaction: rash, itching, swelling or anaphylaxis in rare cases.

When prescribing Nefrocitran, clinicians should consider several safety precautions to minimize risks. - Renal function: assess kidney function before use, as impaired excretion may increase potassium levels. - Serum potassium: monitor potassium concentrations regularly, especially in patients on other potassium‑sparing agents. - Acid‑base status: check blood pH and bicarbonate to avoid over‑correction to alkalosis. - Concomitant medications: review use of ACE inhibitors, ARBs or NSAIDs that may affect potassium balance. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Potassium citrate can interact with other medicines, altering electrolyte balance or drug effectiveness.

Major Interactions (Avoid): - ACE inhibitors or ARBs: combined use may precipitate hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): risk of excessive potassium accumulation. - Sodium bicarbonate: additive alkalinizing effect may cause metabolic alkalosis.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce renal potassium excretion, increasing serum potassium. - Digoxin: elevated potassium can affect digoxin toxicity monitoring. - Certain antibiotics (e.g., trimethoprim‑sulfamethoxazole): can impair potassium excretion.